Cardiovascular actions of buflomedil and possible mechanisms involved.

Cardiovascular effects of buflomedil (Bufedil) were studied in dogs, rabbits and guinea pigs. 1. In pentobarbital-anesthetized dogs, buflomedil (0.32-5.12 mg/kg i.v.) induced a dose-dependent fall of blood pressure and a slight increase of heart rate at 0.32-1.28 mg/kg but a heart rate decrease at 2.56 and 5.12 mg/kg. 2. Buflomedil administered into the maxillary (10-320 micrograms/kg), internal carotid (40-320 micrograms/kg) and vertebral artery (20-640 micrograms/kg) increased respective blood flows dose-dependently. 3. Buflomedil (i.v.) also produced dose-dependent increases of the maxillary blood flow at 0.08-0.64 mg/kg, internal carotid flow at 1.28-5.12 mg/kg and vertebral flow at 0.32-5.12 mg/kg, respectively. These increasing effects were attenuated at larger doses because of marked hypotension. 4. Buflomedil (10 mg/kg i.v.) reduced pressor responses to norepinephrine (noradrenaline) and enhanced depressor responses to isoprenaline (isoproterenol), without affecting depressor responses to acetylcholine and positive chronotropic responses to norepinephrine and isoprenaline. 5. After buflomedil (i.v.), the femoral and coronary blood flow increased dose-dependently while renal blood flow decreased. These increasing effects were also reduced at larger doses because of hypotension. 6. Buflomedil (i.v.) induced a dose-dependent increase of cardiac output at 0.16-0.64 mg/kg, biphasic changes at 1.28 and 2.56 mg/kg and a marked decrease and subsequent slight increase at a large dose of 5.12 mg/kg. 7. 4-Desmethylbuflomedil (i.v.); elicited dose-dependent biphasic changes of blood pressure at 0.64-5.12 mg/kg, and a slight increase of heart rate at 0.32-2.56 mg/kg but decreases at 5.12 mg/kg. It also elevated, dose-dependently, the maxillary blood flow at 0.16-5.12 mg/kg and vertebral flow at 1.28-5.12 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

Cardiovascular effects of 1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl) ethanol and possible mechanisms involved.

Cardiovascular effects of NC-1100 (1-(3,4-dimethoxyphenyl)-2-(4-diphenylmethylpiperazinyl)ethanol and possible modes of action were studied in dogs and guinea pigs. 1. In pentobarbital-anesthetized dogs, intravenous administration of NC-1100 (0.05-1.6 mg/kg) induced a dose-dependent fall of blood pressure, a bradycardia followed by temporal tachycardia, a slight and transient stimulation of respiration and a prolongation of the R-R interval with slight augmentations of P, R and T waves in ECG. 2. In pentobarbital-anesthetized dogs, NC-1100 (2.5-80 micrograms/kg) administered to the maxillary and vertebral artery dose-dependently increased the blood flow in the respective artery. 3. Intravenous administration of NC-1100 (0.05-1.6 mg/kg) also exhibited dose-dependent increases of the maxillary and vertebral blood flow, though the increase in maxillary flow was a little reduced at a high dose of 1.6 mg/kg. Intravenous administration of NC-1100 (0.1-1.6 mg/kg) caused a slight increase in the aortic and coronary blood flow, a decrease in renal flow and a slight and transient decrease followed by an increase in femoral flow. 4. In pentobarbital-anesthetized dogs, NC-1100 (1 mg/kg) administered i.v. did not affect responses of blood pressure and heart rate to norepinephrine and isoprenaline (isoproterenol) but slightly inhibited hypotensive responses to acetylcholine. NC-1100 had no effect on hypertension elicited by carotid sinus reflex and on bradycardia by vagus stimulation. NC-1100 slightly inhibited the tachycardia elicited by pre- as well as postganglionic stellate stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)